Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia

Affiliations

Comment

William T Carpenter Jr et al. JAMA Psychiatry. 2015 Aug.

. 2015 Aug;72(8):745-6.

doi: 10.1001/jamapsychiatry.2015.0485.

¹ Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore.

No abstract available

Comment on

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW. Berwaerts J, et al. JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241. JAMA Psychiatry. 2015. PMID: 25820612 Clinical Trial.
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH. Subotnik KL, et al. JAMA Psychiatry. 2015 Aug;72(8):822-9. doi: 10.1001/jamapsychiatry.2015.0270. JAMA Psychiatry. 2015. PMID: 26107752 Free PMC article. Clinical Trial.